We recruited CKD patients (n=120) in outpatient department and healthy volunteers (n=31) from Seoul National University Hospital for the clinical study, 'Measurement of glomerular filtration rate and calculation of GFR estimates for Korean' granted by the Korean Society of Nephrology from April 2008 to February 2009. All of volunteers showed normal urinalysis and their systemic inulin clearances were greater than 60 mL/min/1.73 m2 (66.4-151.3 mL/min/1.73 m2). Inclusion criteria were as follows: 1) participants who agreed with the study and voluntarily signed on informed consent, 2) aged 18 yr or older. Exclusion criteria of this study were as follows: 1) rapid decline of renal function within 3 months, 2) edema or ascites, 3) proteinuria greater than 10 g/day or serum albumin less than 2.5 g/dL, 4) active infection, 5) coronary artery intervention i.e., coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) within 1 yr (except stabilization after unstable angina or heart failure), 6) liver enzyme abnormality (serum AST/ALT greater than 2×upper normal range), 7) history of severe allergy like angioedema, 8) pregnant or lactating women, 9) gross hematuria, 10) oliguria less than 500 mL/day), 11) renal replacement therapy. This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 0701-006-193).
>
Disorders
>
Disease or Syndrome
>
Oliguria
Oliguria
Oliguria: A condition characterized by a reduced urine output, typically less than 500 milliliters per day.
This reduction in urine volume can signify underlying kidney dysfunction or other medical conditions.
Proper identification and management of oliguria is crucial for maintaining fluid balance and preventing complications.
PubCompare.ai's AI-powered platform can help researchers optimize their oliguria studies by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverageing intelligent comparisons, the platform empowers researchers to identify the most effective solutions for their oliguria studies and streamline their research workflow to drive meaningful insights.
This reduction in urine volume can signify underlying kidney dysfunction or other medical conditions.
Proper identification and management of oliguria is crucial for maintaining fluid balance and preventing complications.
PubCompare.ai's AI-powered platform can help researchers optimize their oliguria studies by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverageing intelligent comparisons, the platform empowers researchers to identify the most effective solutions for their oliguria studies and streamline their research workflow to drive meaningful insights.
Most cited protocols related to «Oliguria»
Angina, Unstable
Angioedema
Ascites
Congestive Heart Failure
Coronary Artery Bypass Surgery
Edema
Enzymes
Healthy Volunteers
Hematuria
Hypersensitivity
Infection
Inulin
Kidney
Koreans
Liver
Oliguria
Outpatients
Patients
Percutaneous Coronary Intervention
Renal Replacement Therapy
Serum
Serum Albumin
Urinalysis
Voluntary Workers
Woman
Angina, Unstable
Closure, Hospital
Common Cold
Congestive Heart Failure
Cyanosis
Diagnosis
Inpatient
Long-Term Care
Oliguria
Patient Discharge
Patients
Respiratory Diaphragm
Shock, Cardiogenic
Syndrome
Systolic Pressure
We recruited adults aged over 18 years to sign informed consents from the Kaohsiung Medical University Hospital and the National Taiwan University Hospital. Subjects with acute renal failure, allergy to inulin, pregnancy, problems in voiding, amputation, congestive heart failure, cirrhosis with ascites, use of cimetidine or trimethoprim, oliguria, and those who had ever received any renal replacement therapy were excluded. Healthy volunteers were enrolled according to the percentage of age distribution in Taiwanese reported by the Ministry of the Interior of Taiwan. CKD was diagnosed and classified according to the K/DOQI clinical guidelines [1] (link). The ratio of the number of the CKD patients to healthy volunteers was approximately 2∶1 in this study.
Full text: Click here
Adult
Amputation
Ascites
Cimetidine
Congestive Heart Failure
Healthy Volunteers
Hypersensitivity
Inulin
Kidney Failure, Acute
Liver Cirrhosis
Oliguria
Patients
Pregnancy
Renal Replacement Therapy
Trimethoprim
The medical charts of 356 typical HFRS patients who were treated in the Center for Infectious Diseases, Tangdu Hospital, between January 2008 and August 2012 were selected randomly and reviewed. The diagnosis of HFRS was made based upon the detection of specific IgM and IgG antibodies to HTNV in acute phase serum specimens by enzyme-linked immunosorbent assay (ELISA).
Based upon clinical classification of HFRS [15 ], the patients were classified into four types: (1) mild, defined as patients who had kidney injury without oliguria and hypotension; (2) moderate, defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria; (3) severe, defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50–500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days; (4) critical, defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50–500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days. Commonly, the so-called acute stage of the disease is defined as the period of febrile, hypotensive and oliguric phases. Overall, 75 cases were classified as critical type and were enrolled in this study. Furthermore, the outcome was defined as death or survival during the interval of being in hospital and after discharge with following up.
Based upon clinical classification of HFRS [15 ], the patients were classified into four types: (1) mild, defined as patients who had kidney injury without oliguria and hypotension; (2) moderate, defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria; (3) severe, defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50–500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days; (4) critical, defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50–500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days. Commonly, the so-called acute stage of the disease is defined as the period of febrile, hypotensive and oliguric phases. Overall, 75 cases were classified as critical type and were enrolled in this study. Furthermore, the outcome was defined as death or survival during the interval of being in hospital and after discharge with following up.
Full text: Click here
Acute Disease
Anuria
Cerebral Edema
Communicable Diseases
Conjunctiva, Bulbar
Diagnosis
Enzyme-Linked Immunosorbent Assay
Fever
Heart Failure
Hemorrhage
Hemorrhagic Fever with Renal Syndrome
Immunoglobulin G
Injuries
Kidney
Mucous Membrane
Oliguria
Patient Discharge
Patients
Peritoneum
Pleura
Pulmonary Edema
Secondary Infections
Serum
Shock
Skin
Uremia
Urine
Medical records of 291 patients were collected from January 1, 2003 to April 30, 2016. Of these, 28 underwent more than one CRRT treatment run. Final analysis was done by removing duplicates and leaving only the longest CRRT run.
During the study period, patients undergoing CRRT were included and grouped as before SCT (group A) and after SCT (group B). Group A included patients treated from March 2003 to July 2008 and group B those from August 2008 to April 2016. Before SCT, pediatric CRRT was run by occasional operators, but after the SCT began, ICU nurses joined and began to work as the member of SCT. Double-lumen catheters ranging between 6.5 and 13.5 F in diameter (Gambro Healthcare, Lakewood, CO, USA) were inserted into the central veins depending on the child’s age and weight. Polyarylethersulfone hollow-fiber hemofilters (PAES; the Prismaflex® HF20, Gambro Lundia AB, Lund, Sweden) and polyacrilonytrile hollow-fiber hemofilters (① AN69® membrane before the year 2010; the Prismaflex® M-10/60/100, Gambro Lundia AB, Lund, Sweden; ② AN69® ST membrane since the year 2010; the Prismaflex® ST-60/100, Gambro Lundia AB, Lund, Sweden) were used in all patients, depending on the patient’s weight. HF-20 or M-10 were used in children weighing less than 10 kg; ST-60 or M-60 were used in patients weighing 10–20 kg, and ST-100 or M-100 were used in children weighing more than 20 kg. Commercially prepared bicarbonate-buffered hemofiltration replacement fluid (Hemosol B0; Gambro Healthcare, Seoul, Korea; potassium free), was used as a dialysate and replacement fluid. Potassium chloride (KCl) was added if the patient has a risk of hypokalemia (20 mEq KCl mix in the 5L Hemozol® when serum potassium level ranged from 3.6 to 4.5 mEg/L and 40 mEq KCl mix in the 5L Hemozol® when serum potassium level lowered than 3.6 mEg/L). The blood flow rate was set as 5 mL/kg/min [18 (link)]. The predilution replacement fluid rate or dialysate rate was set at a rate of 2000 mL/1.73 m2/hour [18 (link)]. The mode of CRRT was selected from one of the following, depending on the patient’s status of solute imbalance: continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF). These were determined by the pediatric nephrologist and pediatric intensivist through in-depth discussion.
The time to initiate CRRT was decided by the pediatric intensivist, depending on each patient’s clinical condition, such as anuria, oliguria (<0.5 mL/kg/hour), or positive fluid balance, regardless of administration of high doses of diuretics (furosemide more than 1 mg/kg/hour). Anticoagulation was not administered during CRRT initiation; however, our protocol establishes that if the filter was blocked within 12 hours of CRRT initiation, anticoagulation agents such as continuous heparin or nafamostat mesilate infusion via the pre-blood pump port were used. The percentage of fluid overload at CRRT initiation (%FO) was calculated using the following formula [20 (link)]:
At the initiation of CRRT, the following data were obtained for all patients: sex, age, diagnosis, underlying patient conditions, blood flow rate, use of inotropic agents, anticoagulants, and hours to starting CRRT.
During the study period, patients undergoing CRRT were included and grouped as before SCT (group A) and after SCT (group B). Group A included patients treated from March 2003 to July 2008 and group B those from August 2008 to April 2016. Before SCT, pediatric CRRT was run by occasional operators, but after the SCT began, ICU nurses joined and began to work as the member of SCT. Double-lumen catheters ranging between 6.5 and 13.5 F in diameter (Gambro Healthcare, Lakewood, CO, USA) were inserted into the central veins depending on the child’s age and weight. Polyarylethersulfone hollow-fiber hemofilters (PAES; the Prismaflex® HF20, Gambro Lundia AB, Lund, Sweden) and polyacrilonytrile hollow-fiber hemofilters (① AN69® membrane before the year 2010; the Prismaflex® M-10/60/100, Gambro Lundia AB, Lund, Sweden; ② AN69® ST membrane since the year 2010; the Prismaflex® ST-60/100, Gambro Lundia AB, Lund, Sweden) were used in all patients, depending on the patient’s weight. HF-20 or M-10 were used in children weighing less than 10 kg; ST-60 or M-60 were used in patients weighing 10–20 kg, and ST-100 or M-100 were used in children weighing more than 20 kg. Commercially prepared bicarbonate-buffered hemofiltration replacement fluid (Hemosol B0; Gambro Healthcare, Seoul, Korea; potassium free), was used as a dialysate and replacement fluid. Potassium chloride (KCl) was added if the patient has a risk of hypokalemia (20 mEq KCl mix in the 5L Hemozol® when serum potassium level ranged from 3.6 to 4.5 mEg/L and 40 mEq KCl mix in the 5L Hemozol® when serum potassium level lowered than 3.6 mEg/L). The blood flow rate was set as 5 mL/kg/min [18 (link)]. The predilution replacement fluid rate or dialysate rate was set at a rate of 2000 mL/1.73 m2/hour [18 (link)]. The mode of CRRT was selected from one of the following, depending on the patient’s status of solute imbalance: continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF). These were determined by the pediatric nephrologist and pediatric intensivist through in-depth discussion.
The time to initiate CRRT was decided by the pediatric intensivist, depending on each patient’s clinical condition, such as anuria, oliguria (<0.5 mL/kg/hour), or positive fluid balance, regardless of administration of high doses of diuretics (furosemide more than 1 mg/kg/hour). Anticoagulation was not administered during CRRT initiation; however, our protocol establishes that if the filter was blocked within 12 hours of CRRT initiation, anticoagulation agents such as continuous heparin or nafamostat mesilate infusion via the pre-blood pump port were used. The percentage of fluid overload at CRRT initiation (%FO) was calculated using the following formula [20 (link)]:
At the initiation of CRRT, the following data were obtained for all patients: sex, age, diagnosis, underlying patient conditions, blood flow rate, use of inotropic agents, anticoagulants, and hours to starting CRRT.
Full text: Click here
Anticoagulants
Anuria
Bicarbonates
BLOOD
Blood Circulation
Cardiac Arrest
Catheters
Child
Continuous Venovenous Hemodiafiltration
Continuous Venovenous Hemodialysis
Diagnosis
Dialysis Solutions
Diuretics
Fibrosis
Fluid Balance
Furosemide
Hemofiltration
Heparin
Infusion Pump
nafamostat mesilate
Nephrologists
Nurses
Oliguria
Patients
phenyl-2-aminoethyl sulfide
Potassium
Serum
Tissue, Membrane
Veins
Venovenous Hemofiltration, Continuous
Most recents protocols related to «Oliguria»
Study design
We performed a retrospective analysis utilizing SUNY Upstate University Hospital data from January 2016 to March 2022 to assess transplant outcomes and biopsies. The data were collected from the electronic medical record system (EPIC). Inclusion required patients who received a renal transplant and adult recipients (> 16 years old). Simultaneous kidney-pancreas, other multiorgan transplant recipients, pediatrics (<16 years old), and mortality in 30 days were excluded. A renal biopsy was done at the center by the transplant surgeon, and the result was reported by the pathologist at SUNY Upstate Medical University’s pathology department. The study population was divided into two subgroups: non-protocol biopsies and protocol biopsies within the 12 months post-transplant. The non-protocol biopsy cases were patients who presented with an alarm sign for possible rejection, such as an increase in serum creatinine above the patient’s baseline value, unexplained fever, edema, hypertension, oliguria, anuria, and proteinuria unrelated to glomerulonephritis with the first 12 months post-kidney transplant. Protocol biopsies were within the first 12 months post-transplant in patients with stable serum creatinine and without any clinical manifestation suspected of kidney rejection. The baseline characteristics of the groups of interest were compared. The graft rejection types were reported by the pathologist as antibody-mediated rejection (ABMR), T-cell mediated rejection (TCMR), borderline rejection (BR-L), and mixed rejection with both antibody-mediated and T-cell mediated rejection at the same time. The Banff 2013 rejection criteria and components were implanted to assess and compare the histopathological features of rejection in each group as the protocol [17 ].
Outcome definitions
The primary objective was to assess the protocol biopsies results, compare the outcomes with the kidney recipients that did not have the protocol biopsies as part of their post-transplant screening, and compare the acute rejection rate and graft failure. The secondary objective was to assess how protocol biopsies could improve the patient and graft survival rates.
Statistical analyses
The primary analyses measured the baseline characteristics in the groups of interest. The t-test and analysis of variance (ANOVA) performed univariate analysis for continuous variables, chi-square test for categorical variables, and Kaplan-Meier curves to assess patient and graft survival rates. Categorical data were summarized as proportions and percentages, and continuous data were summarized as means and standard deviations. A P-value of <0.05 was considered significant, and a P-value of < 0.1 was considered a trend.
We performed a retrospective analysis utilizing SUNY Upstate University Hospital data from January 2016 to March 2022 to assess transplant outcomes and biopsies. The data were collected from the electronic medical record system (EPIC). Inclusion required patients who received a renal transplant and adult recipients (> 16 years old). Simultaneous kidney-pancreas, other multiorgan transplant recipients, pediatrics (<16 years old), and mortality in 30 days were excluded. A renal biopsy was done at the center by the transplant surgeon, and the result was reported by the pathologist at SUNY Upstate Medical University’s pathology department. The study population was divided into two subgroups: non-protocol biopsies and protocol biopsies within the 12 months post-transplant. The non-protocol biopsy cases were patients who presented with an alarm sign for possible rejection, such as an increase in serum creatinine above the patient’s baseline value, unexplained fever, edema, hypertension, oliguria, anuria, and proteinuria unrelated to glomerulonephritis with the first 12 months post-kidney transplant. Protocol biopsies were within the first 12 months post-transplant in patients with stable serum creatinine and without any clinical manifestation suspected of kidney rejection. The baseline characteristics of the groups of interest were compared. The graft rejection types were reported by the pathologist as antibody-mediated rejection (ABMR), T-cell mediated rejection (TCMR), borderline rejection (BR-L), and mixed rejection with both antibody-mediated and T-cell mediated rejection at the same time. The Banff 2013 rejection criteria and components were implanted to assess and compare the histopathological features of rejection in each group as the protocol [17 ].
Outcome definitions
The primary objective was to assess the protocol biopsies results, compare the outcomes with the kidney recipients that did not have the protocol biopsies as part of their post-transplant screening, and compare the acute rejection rate and graft failure. The secondary objective was to assess how protocol biopsies could improve the patient and graft survival rates.
Statistical analyses
The primary analyses measured the baseline characteristics in the groups of interest. The t-test and analysis of variance (ANOVA) performed univariate analysis for continuous variables, chi-square test for categorical variables, and Kaplan-Meier curves to assess patient and graft survival rates. Categorical data were summarized as proportions and percentages, and continuous data were summarized as means and standard deviations. A P-value of <0.05 was considered significant, and a P-value of < 0.1 was considered a trend.
Full text: Click here
Adult
Anuria
Biopsy
Creatinine
Edema
Fever
Glomerulonephritis
Graft Rejection
Grafts
Graft Survival
High Blood Pressures
Immunoglobulins
Interest Groups
Kidney
Kidney Transplantation
Oliguria
Pancreas
Pathologists
Patients
Serum
Surgeons
T-Lymphocyte
Transplant Recipients
We considered serum creatinine at the last medical appointment before hospital admission for HSCT to be baseline serum creatinine. Baseline glomerular filtration rate was estimated according to CKD-EPI equation [10 (link)], using baseline serum creatinine.
AKI diagnosis was made based on daily values of serum creatinine and 6-h urinary output since the time of hospital admission for HSCT until hospital discharge, as well as all other hospital admissions or weekly evaluation in outpatient clinic in the first 100 d after HSCT. AKI was defined by KDIGO criteria [7 ] (any of the following: Increase in serum creatinine by ≥0.3 mg/dl (≥26.5 µmol/l) within 48 h; or increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 d; or urinary output <0.5 ml/kg/h for 6 h). Stage of AKI followed KDIGO classification considering the worst serum creatinine value and/or longest period of urinary volume reduction during hospital stay for HSCT. Moderate to severe AKI was defined as AKI stage 2 and AKI stage 3.
CKD was defined as a persistent decrease in eGFR to below 60 ml/min/1.73 m2, according to the definition of KDIGO [11 (link)].
The hematopoietic cell transplantation – specific comorbidity index (HCT-CI) [12 (link)] was calculated according to the latest validated version considering patients comorbidities. Shock was considered when patients presented with cardiac frequency >90 bpm, systolic blood pressure <90 mmHg, and at least one lactate determination >2 mmol/l or 22 mg/dl.
Nephrotoxic drugs included gentamicin, amikacin, vancomycin, amphotericin B, and foscarnet.
AKI diagnosis was made based on daily values of serum creatinine and 6-h urinary output since the time of hospital admission for HSCT until hospital discharge, as well as all other hospital admissions or weekly evaluation in outpatient clinic in the first 100 d after HSCT. AKI was defined by KDIGO criteria [7 ] (any of the following: Increase in serum creatinine by ≥0.3 mg/dl (≥26.5 µmol/l) within 48 h; or increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 d; or urinary output <0.5 ml/kg/h for 6 h). Stage of AKI followed KDIGO classification considering the worst serum creatinine value and/or longest period of urinary volume reduction during hospital stay for HSCT. Moderate to severe AKI was defined as AKI stage 2 and AKI stage 3.
CKD was defined as a persistent decrease in eGFR to below 60 ml/min/1.73 m2, according to the definition of KDIGO [11 (link)].
The hematopoietic cell transplantation – specific comorbidity index (HCT-CI) [12 (link)] was calculated according to the latest validated version considering patients comorbidities. Shock was considered when patients presented with cardiac frequency >90 bpm, systolic blood pressure <90 mmHg, and at least one lactate determination >2 mmol/l or 22 mg/dl.
Nephrotoxic drugs included gentamicin, amikacin, vancomycin, amphotericin B, and foscarnet.
Full text: Click here
Amikacin
Amphotericin B
Creatinine
Diagnosis
EGFR protein, human
Foscarnet
Gentamicin
Glomerular Filtration Rate
Heart
Lactates
Oliguria
Patient Discharge
Patients
Pharmaceutical Preparations
Serum
Shock
Systolic Pressure
Transplantation, Hematopoietic Stem Cell
Urine
Vancomycin
We investigated the REAC files for the comprehensive Medical Dictionary for Regulatory Activities (MedDRA v23.1). MedDRA defined terms related to renal AEs as follows: “acute kidney injury,” “subacute kidney injury,” “kidney failure,” “oliguria,” “anuria,” “dialysis,” “proteinuria,” “hematuria,” “blood creatinine increased,” “blood urea increased,” “nephritis,” “nephritis toxic,” “tubulointerstitial nephritis,” “renal tubular injury,” “glomerulonephritis acute,” “glomerulonephritis rapid progressive,” “autoimmune nephritis,” “glomerulonephritis membranous,” “glomerulonephritis minimal lesion,” “glomerulonephritis membranoproliferative,” “glomerulonephritis proliferative,” “nephritic syndrome,” “thrombotic microangiopathy.” We chose generic and brand names of anti-VEGF regimes by utilizing the MICROMEDEX (Index Nominum) as a dictionary in the data mining process. The assessment considered drugs recorded as “Primary Suspect” or “Secondary Suspect” (PS an SS in role code field) and routed as “INTRAVITREAL.”
Full text: Click here
Anuria
BLOOD
Creatinine
Dialysis
Generic Drugs
Glomerulonephritis
Glomerulonephritis, Membranoproliferative
Hematuria
Injuries
Kidney
Kidney Failure
Kidney Injury, Acute
Membranous Glomerulonephritis
Nephritis
Nephritis, Tubulointerstitial
Oliguria
Pharmaceutical Preparations
Syndrome
Thrombotic Microangiopathies
Tubule, Kidney
Urea
Vascular Endothelial Growth Factors
We identified ten consecutive patients who developed TMA between 2005-2020, while receiving treatment with carfilzomib at the University of Athens in Greece or at the Dana Farber Cancer Institute in the United States. A clinical diagnosis of carfilzomib-induced TMA was made based on the fulfillment of the following criteria: active carfilzomib treatment; new onset of microangiopathic hemolytic anemia with decreased haptoglobin, thrombocytopenia and evidence of schistocytes on peripheral blood smear; oliguric, acute kidney injury network (AKI), AKIN ≥I (defined as a rise in serum creatinine relative to baseline of at least 1.5 times or 0.3 mg/dl and reduced urine output to less than 0.5 mL/kg/h within 48 h); in the absence of an acute infectious process, decreased ADAMTS13 activity and positive Coombs test. The control group included 10 patients treated with carfilzomib at the same institutions during 2015–2021 and who did not develop TMA. Controls were matched to the patient cohort based on age, gender, carfilzomib dose/duration and use/type of anti-platelet/anticoagulant agent. All subjects in the study were enrolled in IRB-approved protocols at the respective institutions. This study was conducted in accordance with the Declaration of Helsinki.
Full text: Click here
ADAMTS13 protein, human
Anticoagulants
BLOOD
Blood Platelets
carfilzomib
Congenital Thrombotic Thrombocytopenic Purpura
Coombs Test
Creatinine
Diagnosis
Haptoglobins
Infection
Kidney Failure, Acute
Malignant Neoplasms
Oliguria
Patients
Satisfaction
Serum
Thrombocytopenia
A cross-sectional survey of increasingly complex potential deceased kidney donor
cases was developed by one of the study investigators with input from the study
steering committee. The survey was translated into French by a professional
translator with the French version subsequently corrected by a French-speaking
transplant nephrologist.
Survey questions are presented inSupplemental Table 1 . There were 3 sections examining different
kidney donor offer scenarios (Section 1: 8 questions; Section 2: 8 questions;
Section 3: 16 questions) and respondents were asked whether they would accept or
decline a hypothetical donor presented in the question stem, assuming there was
a suitable recipient. Within each Section, donor cases were sequentially adapted
to become increasingly complex (eg, in Section 1, a 40-year-old neurological
determination of death (NDD) donor with normal renal function (Profile 1a), then
a 40-year-old NDD donor with acute kidney injury (AKI) (Profile 2a), then a
40-year-old NDD donor with severe AKI but reassuring biopsy findings (3a), then
a 40-year-old NDD donor with severe AKI and no biopsy (4a)). Within Section 1
this was then repeated, except with a donation after cardiac death (DCD) donor
(Profiles 1b-4b). Respondents were presented the base cases for each donor
scenario in each Section (Profiles 1a, b, c & d,Supplemental Table 1 ) but using skip logic and conditional
branching they were only provided the next level of donor complexity within that
Section if they accepted the donor in the prior scenario. Given the graduated
increased complexity of each donor case, it was assumed that when a respondent
declined a base donor in a particular scenario, they would also decline all
downstream adaptations to that base stem. For example, if a respondent declined
a 40-year-old NDD donor with normal kidney function (Section 1, Profile 1a),
they would automatically be considered as declining the more complex and
higher-risk donors from Section 1, Profile 2a (the same donor now with
non-oliguric AKI) and 3a (the same donor now with oliguric and
dialysis-dependent AKI). When a respondent first declined a potential deceased
donor, they were asked to select all reasons for their decision, categorized as
Donor age, NDD vs. DCD, kidney function, severity of AKI event, biopsy results,
other.
In Sections 1 and 2, base donor cases were primarily stratified by mode of death
(NDD or DCD) and donor age (40 or 60 years), with respondents being prompted to
indicate if either of these factors influenced their decisions. Conversely, in
Section 3, donor cases were stratified by mode of death and donor sex rather
than age (fixed at 65 years). It should be noted that the creatinine values
varied between profiles on the basis of sex which resulted in a higher estimated
glomerular filtration rate (eGFR) for the female recipient (eGFR by
CKD-Epi2021 101 mL/min/1.73 m2 for the 65-year-old
female with admission creatinine 50 umol/L versus 77 mL/min/1.73 m2for the 65-year-old male with admission creatinine 95 umol/L).
cases was developed by one of the study investigators with input from the study
steering committee. The survey was translated into French by a professional
translator with the French version subsequently corrected by a French-speaking
transplant nephrologist.
Survey questions are presented in
kidney donor offer scenarios (Section 1: 8 questions; Section 2: 8 questions;
Section 3: 16 questions) and respondents were asked whether they would accept or
decline a hypothetical donor presented in the question stem, assuming there was
a suitable recipient. Within each Section, donor cases were sequentially adapted
to become increasingly complex (eg, in Section 1, a 40-year-old neurological
determination of death (NDD) donor with normal renal function (Profile 1a), then
a 40-year-old NDD donor with acute kidney injury (AKI) (Profile 2a), then a
40-year-old NDD donor with severe AKI but reassuring biopsy findings (3a), then
a 40-year-old NDD donor with severe AKI and no biopsy (4a)). Within Section 1
this was then repeated, except with a donation after cardiac death (DCD) donor
(Profiles 1b-4b). Respondents were presented the base cases for each donor
scenario in each Section (Profiles 1a, b, c & d,
branching they were only provided the next level of donor complexity within that
Section if they accepted the donor in the prior scenario. Given the graduated
increased complexity of each donor case, it was assumed that when a respondent
declined a base donor in a particular scenario, they would also decline all
downstream adaptations to that base stem. For example, if a respondent declined
a 40-year-old NDD donor with normal kidney function (Section 1, Profile 1a),
they would automatically be considered as declining the more complex and
higher-risk donors from Section 1, Profile 2a (the same donor now with
non-oliguric AKI) and 3a (the same donor now with oliguric and
dialysis-dependent AKI). When a respondent first declined a potential deceased
donor, they were asked to select all reasons for their decision, categorized as
Donor age, NDD vs. DCD, kidney function, severity of AKI event, biopsy results,
other.
In Sections 1 and 2, base donor cases were primarily stratified by mode of death
(NDD or DCD) and donor age (40 or 60 years), with respondents being prompted to
indicate if either of these factors influenced their decisions. Conversely, in
Section 3, donor cases were stratified by mode of death and donor sex rather
than age (fixed at 65 years). It should be noted that the creatinine values
varied between profiles on the basis of sex which resulted in a higher estimated
glomerular filtration rate (eGFR) for the female recipient (eGFR by
CKD-Epi2021 101 mL/min/1.73 m2 for the 65-year-old
female with admission creatinine 50 umol/L versus 77 mL/min/1.73 m2for the 65-year-old male with admission creatinine 95 umol/L).
Acclimatization
Biopsy
Cardiac Death
Creatinine
Donors
Filtration
Kidney
Kidney Injury, Acute
Males
Nephrologists
Oliguria
Stem, Plant
Woman
Top products related to «Oliguria»
Sourced in United States, Germany
The Prismaflex is a modular, flexible, and user-friendly dialysis system designed for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) procedures. It provides a comprehensive solution for the management of acute kidney injury, fluid overload, and other critical conditions requiring extracorporeal blood purification.
Sourced in Germany
The MultiFiltrate is a blood purification device used in renal replacement therapy. It is designed to filter and remove waste, electrolytes, and excess fluid from the blood. The MultiFiltrate utilizes a semi-permeable membrane to selectively filter and control the balance of substances in the bloodstream.
Sourced in United States
Prisma is a lab equipment product designed for filtration and separation processes. It serves as a versatile and reliable tool for researchers and laboratories. The core function of Prisma is to enable efficient and precise separation of various components in liquid samples.
Sourced in United States
PETINIA is a laboratory equipment product from Siemens. It is designed for performing precision measurements and analysis tasks in a controlled environment. The core function of PETINIA is to provide accurate and reliable data acquisition and processing capabilities for research and scientific applications.
Sourced in Germany, Poland
The ELISA kit is a laboratory equipment designed for the detection and quantification of specific analytes in a sample. It utilizes an enzyme-linked immunosorbent assay (ELISA) technique to measure the presence and concentration of target molecules. The kit provides the necessary reagents and procedures to perform this analytical method.
Sourced in United States, Japan, United Kingdom, India
SPSS software version 24.0 is a statistical analysis and data management software package developed by IBM. It provides a range of tools for data analysis, including descriptive statistics, bivariate statistics, prediction for numerical outcomes, and prediction for identifying groups. The software is designed to help users analyze and understand complex data sets.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, Ireland
The Bio-Medicus is a blood pump used in medical procedures. It is designed to assist or replace the normal pumping function of the heart during certain medical treatments.
Sourced in United States, Germany, China, France
The Automatic Biochemical Analyzer is a laboratory instrument designed to perform automated chemical analysis of biological samples. Its core function is to measure the concentration of specific analytes, such as proteins, enzymes, and metabolites, in a wide range of sample types, including blood, urine, and other bodily fluids.
Sourced in United States, United Kingdom, Japan, Thailand, China, Italy, Germany
SPSS version 18.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The core function of SPSS is to assist in the analysis of data and presentation of results.
More about "Oliguria"
Oliguria, a medical condition marked by reduced urine output, typically less than 500 milliliters per day, can signal underlying kidney dysfunction or other health issues.
Proper identification and management of oliguria is crucial for maintaining fluid balance and preventing complications.
PubCompare.ai's AI-powered platform helps researchers optimize their oliguria studies by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leveraging intelligent comparisons, the platform empowers researchers to identify the most effective solutions for their oliguria studies and streamline their research workflow to drive meaningful insights.
Researchers can utilize tools like Prismaflex, MultiFiltrate, and Prisma to manage fluid balance in oliguria patients, while PETINIA and ELISA kits can be used to assess kidney function.
SPSS software version 24.0 and 18.0 can assist with statistical analysis of oliguria data.
Other related terms and subtopics include anuria (complete lack of urine output), hypovolemia (low blood volume), acute kidney injury (AKI), chronic kidney disease (CKD), Simulect (an immunosuppressant drug), Bio-Medicus (a medical device company), and automatic biochemical analyzers for testing kidney biomarkers.
By exploring these insights, researchers can optimize their oliguria studies and uncover valuable findings to improve patient outcomes.
Proper identification and management of oliguria is crucial for maintaining fluid balance and preventing complications.
PubCompare.ai's AI-powered platform helps researchers optimize their oliguria studies by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leveraging intelligent comparisons, the platform empowers researchers to identify the most effective solutions for their oliguria studies and streamline their research workflow to drive meaningful insights.
Researchers can utilize tools like Prismaflex, MultiFiltrate, and Prisma to manage fluid balance in oliguria patients, while PETINIA and ELISA kits can be used to assess kidney function.
SPSS software version 24.0 and 18.0 can assist with statistical analysis of oliguria data.
Other related terms and subtopics include anuria (complete lack of urine output), hypovolemia (low blood volume), acute kidney injury (AKI), chronic kidney disease (CKD), Simulect (an immunosuppressant drug), Bio-Medicus (a medical device company), and automatic biochemical analyzers for testing kidney biomarkers.
By exploring these insights, researchers can optimize their oliguria studies and uncover valuable findings to improve patient outcomes.